McMaster University

McMaster University

John Kelton


Pathology and Molecular Medicine

Executive Director
Michael G. DeGroote Initiative for
Innovation in Healthcare
3H50 Health Sciences Centre

Assistant: Raquel Whitwell ext 21706


John Kelton

Faculty Biography

Education and Professional Standing

  • FRCPC Hematology, 1978
  • FRCPC Internal Medicine, 1977
  • MD, University of Western Ontario (Cum Laude), 1973



Clinical & Research Focus

Dr. John Kelton has an active clinical practice along with a research focus into platelet and bleeding disorders with a particular focus on bleeding disorders of pregnant women and heparin-induced thrombocytopenia. Dr. Kelton’s research contributions have lead to numerous national and international awards for research excellence including his induction as a Fellow of the Royal Society of Canada; the Jean-Julliard Award from the International Society of Blood Transfusion; the Emily Cooley Award from the American Association of Blood Banks; the Bernard L. Schwartz Award from the Scripps Research Institute; most recently, Prix Galien award. He was also awarded the honour of becoming a Member, Order of Canada, in 2015.

Academic Interests

Dr. Kelton is the Executive Director of the Michael G. DeGroote Initiative for Innovation in Healthcare at McMaster University in Hamilton, Ontario, Canada. He took this role after completing, in June 2016, a highly successful 15-year term as Dean and Vice-President of the Faculty of Health Sciences, as well as the Dean of the Michael G. DeGroote School of Medicine. He is the author of five books, more than 80 book chapters, and more than 300 scientific publications including more than 15 original articles in the New England Journal of Medicine. Dr. Kelton graduated (cum laude) from the University of Western Ontario in 1973. Following specialty and research training at Duke University in North Carolina and McMaster University, he joined McMaster’s Faculty of Health Sciences in 1977.

Selected Publications

  • Arnold DM, Nazi I, Santos A, Chan H, Heddle NM, Warkentin TE, Kelton JG. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115(1):29-31.
  • Warkentin TE, Sheppard JI, Moore JC, Kelton JG. Use of well-characterized sera for assessment of new diagnostic enzyme-immunoassays for diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2010; 8(1): 216-218.
  • Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009; 113(20); 4963-4969.
  • Arnold DM, Nazi I, Kelton JG. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. Expert Opin Investig Drugs. 2009;18 (6): 805 – 819.
  • Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, Kelton JG, Crowther MA. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009; 94(6): 850-856.
  • Kelton JG, Hursting MJ, Heddle, N. Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. Blood Coagul Fibrinolysis. 2008; 19(6); 471-5.
  • Kelton JG, Warkentin, TE. Heparin-induced thrombocytopenia: a historical perspective. Blood: 50th Anniversary Special Edition 2008; 112(7); 2607-16.
  • Arnold DM, Smith JW, Kelton JG. Diagnosis and management of neonatal alloimmune thrombocytopenia. Transfus Med Rev. 2008; 22(4); 255-267.
Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0